SPRY Stock Overview
A biopharmaceutical company, develops treatments for severe allergic reactions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ARS Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.82 |
52 Week High | US$11.27 |
52 Week Low | US$2.55 |
Beta | 0 |
1 Month Change | -6.86% |
3 Month Change | 1.50% |
1 Year Change | 29.90% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 45.54% |
Recent News & Updates
Shareholder Returns
SPRY | US Biotechs | US Market | |
---|---|---|---|
7D | -1.0% | 4.2% | 1.8% |
1Y | 29.9% | 8.1% | 22.8% |
Return vs Industry: SPRY exceeded the US Biotechs industry which returned 9% over the past year.
Return vs Market: SPRY exceeded the US Market which returned 23.1% over the past year.
Price Volatility
SPRY volatility | |
---|---|
SPRY Average Weekly Movement | 7.4% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SPRY has not had significant price volatility in the past 3 months.
Volatility Over Time: SPRY's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 25 | Rich Lowenthal | ars-pharma.com |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
ARS Pharmaceuticals, Inc. Fundamentals Summary
SPRY fundamental statistics | |
---|---|
Market cap | US$882.72m |
Earnings (TTM) | -US$49.70m |
Revenue (TTM) | US$10.00k |
Over9,999x
P/S Ratio-17.2x
P/E RatioIs SPRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SPRY income statement (TTM) | |
---|---|
Revenue | US$10.00k |
Cost of Revenue | US$18.75m |
Gross Profit | -US$18.74m |
Other Expenses | US$30.96m |
Earnings | -US$49.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.51 |
Gross Margin | -187,380.00% |
Net Profit Margin | -496,960.00% |
Debt/Equity Ratio | 0% |
How did SPRY perform over the long term?
See historical performance and comparison